This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Top Analyst Reports for AbbVie, ServiceNow & Boeing
by Mark Vickery
AbbVie, ServiceNow, and Boeing outpace their industries as analysts highlight growth drivers and risks in fresh research reports.
Should You Add IDEXX Stock to Your Portfolio Right Now?
by Zacks Equity Research
IDXX shows strong CAG Diagnostics growth, cloud software momentum and global expansion but faces solvency and macro risks.
Is Climb Bio, Inc. (CLYM) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Climb Bio, Inc. (CLYM) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.
Why Is Idexx (IDXX) Down 0.4% Since Last Earnings Report?
by Zacks Equity Research
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Idexx Laboratories (IDXX) Recently Broke Out Above the 20-Day Moving Average
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
DGX Stock Gains Following a New Joint Venture With Corewell Health
by Zacks Equity Research
Quest Diagnostics shares rise after forming a joint venture with Corewell Health to expand advanced lab services across Michigan.
If You Invested $1000 in Idexx Laboratories a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Should You Add IDEXX Stock to Your Portfolio Right Now?
by Zacks Equity Research
IDXX gains from strong CAG Diagnostics growth and rising cloud software demand, but debt levels remain a concern for investors.
Is Encompass Health (EHC) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Encompass Health (EHC) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.
3 Reasons Why Growth Investors Shouldn't Overlook Idexx (IDXX)
by Zacks Equity Research
Idexx (IDXX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
IDEXX Gains 56.2% in a Year: What's Driving the Rally?
by Zacks Equity Research
IDXX shares surge 56.2% in a year, fueled by strong diagnostics growth, cloud software gains and an upbeat 2025 outlook.
Insulet Gains 77.2% in a Year: What's Driving the Rally?
by Zacks Equity Research
PODD's 77.2% stock surge is fueled by Omnipod 5 expansion, global launches, strong Q2 profits and robust financial stability.
Should Boston Scientific Stock Be in Your Portfolio Right Now?
by Zacks Equity Research
BSX's global expansion and MedSurg growth boost Q2 momentum, though currency and macro headwinds weigh on the same.
Here's Why Idexx Laboratories (IDXX) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Teleflex Stock Gains Following Barrigel's Launch in Japan
by Zacks Equity Research
TFX stock jumps 3.7% after launching Barrigel in Japan, marking a milestone in its global expansion strategy.
PAHC Stock Up 76.4% in a Year: What's Driving the Rally?
by Zacks Equity Research
Phibro Animal Health's 76.4% stock surge is fueled by strong sales recovery, global growth and a robust balance sheet.
Labcorp Debuts First FDA-Cleared Blood Test for Alzheimer's, Stock Up
by Zacks Equity Research
LH launches the first FDA-cleared blood test for Alzheimer's, boosting access to early diagnosis and nudging its stock higher.
Here's How Much a $1000 Investment in Idexx Laboratories Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Is Idexx (IDXX) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
Idexx (IDXX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here's Why Idexx Laboratories (IDXX) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Idexx Laboratories (IDXX) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
IDEXX Stock Up on Q2 Earnings & Revenue Beat, Margins Expand
by Zacks Equity Research
IDXX posts double-digit Q2 revenue growth, beats EPS estimates and lifts the full-year outlook as margins rise sharply.
Idexx (IDXX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Idexx (IDXX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Idexx Laboratories (IDXX) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of +9.67% and +4.01%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Integra LifeSciences (IART) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Integra (IART) delivered earnings and revenue surprises of +4.65% and +5.05%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?